Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.32 |
| ▸ | ADH1C | P00326 | 2/20 | 0.32 |
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH7 | P40394 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290199 | 0.87 | ALDH1A1 (0.42) | TSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL502512 | 0.84 | FDPS (0.36) | TSHR | |
| SCHEMBL28422929 | 0.82 | FDPS (0.34) | TSHR | |
| SCHEMBL16290215 | 0.80 | ALDH1A1 (0.38) | TSHRALDH1A1 | |
| SCHEMBL525489 | 0.78 | GGPS1 (0.41) | TSHR | |
| SCHEMBL5028617 | 0.75 | FDPS (0.33) | TSHR | |
| SCHEMBL4597693 | 0.75 | GGPS1 (0.43) | TSHR | |
| SCHEMBL3372046 | 0.75 | GGPS1 (0.43) | TSHR | |
| SCHEMBL7582387 | 0.75 | GGPS1 (0.43) | TSHR | |
| SCHEMBL1784622 | 0.71 | TSHR (0.52) | TSHRFAAHTRPV1ALDH1A1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975831-B2 | Method for producing ether compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20150011799-A1 | METHOD FOR PRODUCING ETHER COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-2813482-A1 | METHOD FOR PRODUCING ETHER COMPOUND | Takasago International Corporation (JP) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011799-A1 | METHOD FOR PRODUCING ETHER COMPOUND | CBR3, CYP2E1, HPD | TSHR 4272/4885FAAH 194/4885TRPV1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.